Targeting BCL-XL for degradation synergizes with gemcitabine against cholangiocarcinoma

Key Points

• The study aims to evaluate the therapeutic potential of targeting BCL-XL in cholangiocarcinoma, particularly in conjunction with gemcitabine to combat treatment resistance.
• Identified XZ739 as a candidate for BCL-XL degradation
• Assessed combination effects of XZ739 with gemcitabine in cell models
• Evaluated hematologic toxicity associated with treatment combinations
• XZ739 effectively degraded BCL-XL in cholangiocarcinoma cells
• Combination of XZ739 with gemcitabine showed enhanced anti-cancer effects
• Treatment decreased hematologic toxicity compared to gemcitabine alone